by [150+ Pages Report] As per the latest Research and survey report issued by Precedence Research, the global psoriasis treatment market was valued at around USD 25.3 billion in 2021 and is expected to register revenues worth USD 51.24 billion by the end of 2030, growing at an exceptional CAGR of approximately 8.16% between 2022 and 2030.
Download Free Sample Copy with TOC@ https://www.precedenceresearch.com/sample/2034
Psoriasis Treatment Market Report Scope
A recent study by Precedence Research on the psoriasis treatment market offers a forecast for 2022 and 2030. The study analyzes crucial trends that are currently determining the growth of the psoriasis treatment market. This report explicates on vital dynamics such as the drivers, restraints, and opportunities for key market players, along with key stakeholders as well as emerging players associated with the manufacturing of psoriasis treatment. The study also provides the dynamics that are responsible for influencing the future status of the psoriasis treatment market over the forecast period.
A detailed assessment of the psoriasis treatment market value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report. A list of prominent companies operating in the psoriasis treatment market along with their product portfolio enhances the reliability of this comprehensive research study.
Competition Landscape
The report has engulfed a chapter on the global psoriasis treatment market’s competitive landscape, which provides detailed analysis and insights on companies offering psoriasis treatment. Profiles of key companies, along with a strategic overview of their M&A and expansion plans across geographies, have been delivered in this chapter. This chapter is priceless for report readers, as its enables them in gauging their growth potential in the market and implement key strategies for extending their market reach.
This chapter offers key recommendations for both new and existing market participants, enabling them to emerge sustainably and profitably. Intelligence on the market players has been delivered on the basis of their product overview, SWOT analysis, key developments, key financials and company overview. Occupancy of these market participants has been tracked by the report and portrayed via an intensity map.
Read Also@ Solid Oxide Fuel Cell Market Size, Report 2022 to 2030
Some of the Prominent Players in the Psoriasis Treatment Market Include:
- Johnson & Johnson Services, Inc. (U.S.)
- Pfizer Inc. (U.S.)
- AbbVie Inc. (U.S.)
- Novartis AG (Switzerland)
- LEO Pharma A/S (Denmark)
- Merck & Co., Inc. (U.S.)
- UCB S.A. (Belgium)
- Sun Pharmaceutical Industries Ltd. (India)
- Amgen Inc. (U.S.)
- Eli Lilly and Company (U.S.)
- Evelo Biosciences, Inc. (U.S.)
Psoriasis Treatment Market Segmentation
By Drug Class
- Interleukins
- TNF Inhibitors
- Others
By Treatment Type
- Biologic Drugs
- Small Molecule Systemic Drugs
- Tropical Therapies
By Type
- Psoriatic Arthritis
- Plaque Psoriasis
- Others
By Route of Administration
- Oral
- Parenteral
- Topical
By Distribution Channel
- Hospital Pharmacies
- Online pharmacies
- Retail Pharmacies
Regional Segmentation
- Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]
- Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
- North America [United States, Canada, Mexico]
- South America [Brazil, Argentina, Columbia, Chile, Peru]
- Middle East & Africa [GCC, North Africa, South Africa]
Regional Analysis
The research report includes a detailed study of regions of North America, Europe, China, Japan and Rest of the World. The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2022 to 2030. These analyses will help the reader to understand the potential worth of investment in a particular region.
The report provides in-depth segment analysis of the global psoriasis treatment market, thereby providing valuable insights at macro as well as micro levels. Analysis of major countries, which hold growth opportunities or account for significant share has also been included as part of geographic analysis of the psoriasis treatment market.
The report includes country-wise and region-wise market size for the period 2022-2030. It also includes market size and forecast by segments in terms of production capacity, price and revenue for the period 2022-2030.
Why should you invest in this report?
If you are aiming to enter the global psoriasis treatment market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for psoriasis treatment are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030 so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Psoriasis Treatment Market
5.1. COVID-19 Landscape: Psoriasis Treatment Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Psoriasis Treatment Market, By Drug Class
8.1. Psoriasis Treatment Market, by Drug Class, 2022-2030
8.1.1. Interleukins
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. TNF Inhibitors
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Others
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Psoriasis Treatment Market, By Treatment Type
9.1. Psoriasis Treatment Market, by Treatment Type, 2022-2030
9.1.1. Biologic Drugs
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Small Molecule Systemic Drugs
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Tropical Therapies
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Psoriasis Treatment Market, By Type
10.1. Psoriasis Treatment Market, by Type, 2022-2030
10.1.1. Psoriatic Arthritis
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Plaque Psoriasis
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Psoriasis Treatment Market, By Route of Administration
11.1. Psoriasis Treatment Market, by Route of Administration, 2022-2030
11.1.1. Oral
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Parenteral
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Topical
11.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Psoriasis Treatment Market, By Distribution Channel
12.1. Psoriasis Treatment Market, by Distribution Channel, 2022-2030
12.1.1. Hospital Pharmacies
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. Online pharmacies
12.1.2.1. Market Revenue and Forecast (2017-2030)
12.1.3. Retail Pharmacies
12.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 13. Global Psoriasis Treatment Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.1.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.1.3. Market Revenue and Forecast, by Type (2017-2030)
13.1.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.1.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.1.6.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.1.6.3. Market Revenue and Forecast, by Type (2017-2030)
13.1.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.1.6.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.1.7.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.1.7.3. Market Revenue and Forecast, by Type (2017-2030)
13.1.7.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.1.7.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.2.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.2.3. Market Revenue and Forecast, by Type (2017-2030)
13.2.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.2.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.2.6.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.2.6.3. Market Revenue and Forecast, by Type (2017-2030)
13.2.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.2.6.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2.7. Germany
13.2.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.2.7.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.2.7.3. Market Revenue and Forecast, by Type (2017-2030)
13.2.7.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.2.7.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2.8. France
13.2.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.2.8.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.2.8.3. Market Revenue and Forecast, by Type (2017-2030)
13.2.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.2.8.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2.9. Rest of Europe
13.2.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.2.9.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.2.9.3. Market Revenue and Forecast, by Type (2017-2030)
13.2.9.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.2.9.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.3.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.3.3. Market Revenue and Forecast, by Type (2017-2030)
13.3.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.3.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.3.6.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.3.6.3. Market Revenue and Forecast, by Type (2017-2030)
13.3.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.3.6.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3.7. China
13.3.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.3.7.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.3.7.3. Market Revenue and Forecast, by Type (2017-2030)
13.3.7.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.3.7.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3.8. Japan
13.3.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.3.8.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.3.8.3. Market Revenue and Forecast, by Type (2017-2030)
13.3.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.3.8.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3.9. Rest of APAC
13.3.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.3.9.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.3.9.3. Market Revenue and Forecast, by Type (2017-2030)
13.3.9.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.3.9.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.4.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.4.3. Market Revenue and Forecast, by Type (2017-2030)
13.4.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.4.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.4.6.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.4.6.3. Market Revenue and Forecast, by Type (2017-2030)
13.4.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.4.6.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4.7. North Africa
13.4.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.4.7.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.4.7.3. Market Revenue and Forecast, by Type (2017-2030)
13.4.7.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.4.7.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4.8. South Africa
13.4.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.4.8.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.4.8.3. Market Revenue and Forecast, by Type (2017-2030)
13.4.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.4.8.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4.9. Rest of MEA
13.4.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.4.9.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.4.9.3. Market Revenue and Forecast, by Type (2017-2030)
13.4.9.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.4.9.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.5.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.5.3. Market Revenue and Forecast, by Type (2017-2030)
13.5.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.5.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.5.6.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.5.6.3. Market Revenue and Forecast, by Type (2017-2030)
13.5.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.5.6.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.5.7. Rest of LATAM
13.5.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.5.7.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.5.7.3. Market Revenue and Forecast, by Type (2017-2030)
13.5.7.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.5.7.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
Chapter 14. Company Profiles
14.1. Johnson & Johnson Services, Inc. (U.S.)
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Pfizer Inc. (U.S.)
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. AbbVie Inc. (U.S.)
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Novartis AG (Switzerland)
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. LEO Pharma A/S (Denmark)
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Merck & Co., Inc. (U.S.)
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. UCB S.A. (Belgium)
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Sun Pharmaceutical Industries Ltd. (India)
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Amgen Inc. (U.S.)
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Eli Lilly and Company (U.S.)
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
Buy This Premium Research Report Click Here@ https://www.precedenceresearch.com/checkout/2034
About Us
Precedence Research is a Canada/India based company and one of the leading providers of strategic market insights. We offer executive-level blueprints of markets and solutions beyond flagship surveys. Our repository covers consultation, syndicated market studies, and customized research reports. Through our services we aim at connecting an organization’s goal with lucrative prospects globally.
From gauging investment feasibility to uncovering hidden growth opportunities, our market studies cover in-depth analysis, which also is interspersed with relevant statistics. Recommendation are often enclosed within our reports with the sole intent of enabling organizations achieve mission-critical success.
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
